217 related articles for article (PubMed ID: 21370720)
1. Alternating Polistes-Vespula venom immunotherapy: a therapeutic strategy to resolve a diagnostic deficiency.
Moreno C; Barasona MJ; Serrano P; Justicia JL; Ruz JM; Guerra F
J Investig Allergol Clin Immunol; 2011; 21(1):28-33. PubMed ID: 21370720
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
Spoerl D; Bircher AJ; Scherer K
J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
[TBL] [Abstract][Full Text] [Related]
3. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
4. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
5. Development of new IgE specificities to hymenoptera allergens during venom-specific immunotherapy.
Tavares B; Rordigues F; Pereira C; Loureiro G; Chieira C
Eur Ann Allergy Clin Immunol; 2005 May; 37(5):171-6. PubMed ID: 15984315
[TBL] [Abstract][Full Text] [Related]
6. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens.
Carballada F; Boquete M; Núñez R; Lombardero M; de la Torre F
J Investig Allergol Clin Immunol; 2010; 20(6):506-13. PubMed ID: 21243935
[TBL] [Abstract][Full Text] [Related]
7. Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study.
Savi E; Incorvaia C; Boni E; Mauro M; Peveri S; Pravettoni V; Quercia O; Reccardini F; Montagni M; Pessina L; Ridolo E
PLoS One; 2017; 12(7):e0180270. PubMed ID: 28686638
[TBL] [Abstract][Full Text] [Related]
8. Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization.
Monsalve RI; Vega A; Marqués L; Miranda A; Fernández J; Soriano V; Cruz S; Domínguez-Noche C; Sánchez-Morillas L; Armisen-Gil M; Guspí R; Barber D
Allergy; 2012 Apr; 67(4):528-36. PubMed ID: 22229815
[TBL] [Abstract][Full Text] [Related]
9. [The wasp/mosquito syndrome].
Sabbah A; Hassoun S; Drouet M; Lauret MG; Doucet M
Allerg Immunol (Paris); 1999 Jun; 31(6):175-84. PubMed ID: 10443298
[TBL] [Abstract][Full Text] [Related]
10. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
11. Component-resolved diagnosis in vespid venom-allergic individuals.
Galindo-Bonilla PA; Galán-Nieto A; Alfaya-Arias T; García-Rodríguez C; de la Roca-Pinzón F; Feo-Brito F
Allergol Immunopathol (Madr); 2015; 43(4):398-402. PubMed ID: 25192862
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of immunotherapy with aluminum hydroxide-adsorbed venom extract of Vespula spp. An open, retrospective study.
Poli F; Longo G; Parmiani S
Allergol Immunopathol (Madr); 2001; 29(5):191-6. PubMed ID: 11720652
[TBL] [Abstract][Full Text] [Related]
13. Natural history of Hymenoptera venom allergy in Eastern Spain.
Fernandez J; Soriano V; Mayorga L; Mayor M
Clin Exp Allergy; 2005 Feb; 35(2):179-85. PubMed ID: 15725189
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity to Vespula and Polistes: can we tell the primary sensitization from the clinical history?
Pérez Pimiento AJ; Vásquez Bautista AA; Prieto Lastra L; Rodríguez Cabreros MI; García Cubero A; Calvo Manuel E
Allergol Immunopathol (Madr); 2007; 35(6):225-7. PubMed ID: 18047811
[TBL] [Abstract][Full Text] [Related]
15. Allergens in hymenoptera venom. IX. Species specificity to Polistes (paper wasp) venoms.
Hoffman DR; McDonald CA
Ann Allergy; 1982 Feb; 48(2):82-6. PubMed ID: 7065471
[TBL] [Abstract][Full Text] [Related]
16. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
Lerch E; Müller UR
J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with wasp venom is accompanied by wide-ranging immune responses that need further exploration.
Brasch J; Maidusch T
Acta Derm Venereol; 2009; 89(5):466-9. PubMed ID: 19734970
[TBL] [Abstract][Full Text] [Related]
18. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
19. [Value of specific IgE and IgG4 measurements in the follow-up of a hymenoptera venom immunotherapy treatment: apropos of 82 cases].
Sonneville A; Loustanau O; Tahar HA; Menelet I
Allerg Immunol (Paris); 2000 Jan; 32(1):20-5. PubMed ID: 10723532
[TBL] [Abstract][Full Text] [Related]
20. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
